A Phase 2 interventional study of CD388 Injection and Placebo in Influenza, sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 63 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.
Among the 966 studies in Influenza, Human with a site in United States, this one is the 80th largest by enrollment of the 843 interventional ones that give a count, is one of 35 that started in 2024, is one of 161 in phase 2, and was the 903rd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
David Moss · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years to 63 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
966 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 244 · Phase 3 127 · Phase 4 147
First in 1997; this study’s year is marked. 35 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,071 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 843 interventional studies, 261 across the 122 observational. Of the 841 that completed or were terminated, 433 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
435 of 966 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Merck & Co., Inc has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
41 of the studies in Influenza, Human with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 41 to your calendar (.ics) → With an account.
Among the 966 studies in Influenza, Human with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.
This is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter dose selection study to evaluate the efficacy, safety, and tolerability of 3 dose levels of CD388 administered as a single dose via 3 SQ injections in adult participants who are not at risk of developing complications from influenza.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of (WOCBP) must:
A woman is considered of childbearing potential (i.e., fertile) following menarche and until becoming , unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
Male participants must wear a condom when engaging in any activity that allows for passage of ejaculate to another person from Day 1 until 32 weeks after study drug administration. Male participants should also be advised of the benefit for a female partner to additionally use a highly effective method of contraception, as condoms could break or leak.
Note: Contraceptive (birth control) use by participants should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are randomized to receive a low dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Combination Product: CD388 Injection
Participants are randomized to receive a medium dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Combination Product: CD388 Injection
Participants are randomized to receive a high dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Combination Product: CD388 Injection
Participants are randomized to receive placebo by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Combination Product: Placebo
CD388 liquid for injection
Placebo to match
Percentage of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with central laboratory-confirmed reverse-transcriptase polymerase chain reaction positive (RT-PCR+) influenza infection based on the nasopharyngeal (NP) swab result, as compared to placebo.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) after Administration of Study Drug
Safety and tolerability of CD388, as compared to placebo, will be evaluated by assessing the number of participants with incidences of TEAEs following the administration of study drug. TEAEs include but are not limited to adverse events (AEs), serious adverse events (SAEs), injection site reactions (ISRs), and any potentially clinically significant changes from baseline seen in vital signs, 12-lead electrocardiograms (ECGs), and clinical laboratory parameters.
Time frame: From Day 1 through Day 197/End of Study (EOS) after study drug dosing
Percentage of Participants Experiencing Protocol-defined ILI Occurring ≥7 Days after and up to 28 Weeks after Administration of Study Drug
Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result, as compared to placebo.
Time frame: From Day 8 up to 28 weeks after study drug dosing
Percentage of Participants Experiencing Protocol-defined ILI (as in Primary Endpoint 1) Except with a Lower Threshold for New Onset of Fever
Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result, as compared to placebo. New onset of fever is defined as oral temperature ≥37.2 degrees Celsius (°C). Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Percentage of Participants Experiencing Protocol-defined ILI (as in Primary Endpoint 1) Except the Influenza Infection is Based on the Midturbinate (MT) Swab Result
Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with the influenza infection based on the MT swab result, as compared to placebo.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Percentage of Participants Experiencing an Influenza Infection AND New Onset of Fever AND New Onset of ≥2 Respiratory Symptoms after Administration of Study Drug
Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. New onset of fever is defined as oral temperature ≥37.8°C. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Percentage of Participants Experiencing an Influenza Infection AND New Onset of ≥2 Respiratory Symptoms after Administration of Study Drug
Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Percentage of Participants Experiencing an Influenza Infection AND New Onset of ≥1 Respiratory Symptom AND New Onset of ≥1 Systemic Symptom after Administration of Study Drug
Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Percentage of Participants Experiencing an Influenza Infection, AND New Onset of ≥2 Respiratory Symptoms, OR ≥1 Respiratory Symptom AND New Onset of ≥1 Systemic Symptom, after Administration of Study Drug
Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Percentage of Participants Experiencing an Influenza Infection AND New Onset of Fever, AND New Onset of ≥2 Respiratory Symptoms, OR New Onset of ≥1 Respiratory Symptom Plus New Onset of ≥1 Systemic Symptom, after Administration of Study Drug
Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection (first occurrence only) from either the self-collected MT swab (collected prior to the initiation of any antiviral treatment) or the NP swab collected by a health professional, occurring after administration of CD388, as compared to placebo. New onset of fever is defined as oral temperature ≥38°C. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.
Time frame: From Day 8 up to 24 weeks after study drug dosing
Severity (as Composite Symptom Score) of Participant Reported Influenza-like Symptoms as Based on the Self-reported Responses to the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) Symptom Scale
Evaluation of the severity (defined as the composite symptom score) of participant reported influenza-like symptoms as based on the self-reported responses to the RiiQ™ Symptom Scale (scored as 0 = none, 1 = mild, 2 = moderate, and 3 = severe) as presented in the participant eDiary. The composite symptom score is defined as the mean of the scores of the non-missing influenza symptoms for each time point. From the time the participant triggers an Acute Respiratory Infection (ARI) Alert in the eDiary until the ARI episode is resolved (defined as 2 consecutive days where all influenza-associated symptoms on the RiiQ™ Symptom Scale have returned to the same severity level as reported at baseline or lower), the participant will complete the RiiQ™ Symptom Scale in the eDiary for a maximum of 29 days, per ARI episode.
Time frame: On Day 1 (pre-dose baseline); and then once daily from the time the participant triggers an ARI Alert in the eDiary until the ARI episode is resolved for a maximum of 29 days per ARI episode, up to 28 weeks after study drug dosing
Severity (as Area Under the Curve [AUC]) of Participant Reported Influenza-like Symptoms as Based on the Self-reported Responses to the RiiQ™ Symptom Scale
Evaluation of the severity (presented as AUC) of participant reported influenza-like symptoms as based on the self-reported responses to the RiiQ™ Symptom Scale (scored as 0 = none, 1 = mild, 2 = moderate, and 3 = severe) as presented in the participant eDiary. AUC will be based on scores of the non-missing influenza symptoms for each time point. From the time the participant triggers an Acute Respiratory Infection (ARI) Alert in the eDiary until the ARI episode is resolved (defined as 2 consecutive days where all influenza-associated symptoms on the RiiQ™ Symptom Scale have returned to the same severity level as reported at baseline or lower), the participant will complete the RiiQ™ Symptom Scale in the eDiary for a maximum of 29 days, per ARI episode.
Time frame: On Day 1 (pre-dose baseline); and then once daily from the time the participant triggers an ARI Alert in the eDiary until the ARI episode is resolved for a maximum of 29 days per ARI episode, up to 28 weeks after study drug dosing
Duration (as Time to Symptom Resolution) of Participant Reported Influenza-like Symptoms as Based on the Self-reported Responses to the RiiQ™ Symptom Scale
Evaluation of the duration (defined as the time from the first report of influenza-associated symptoms to resolution) of participant reported influenza-like symptoms as based on the self-reported responses to the RiiQ™ Symptom Scale (scored as 0 = none, 1 = mild, 2 = moderate, and 3 = severe) as presented in the participant eDiary. From the time the participant triggers an Acute Respiratory Infection (ARI) Alert in the eDiary until the ARI episode is resolved (defined as 2 consecutive days where all influenza-associated symptoms on the RiiQ™ Symptom Scale have returned to the same severity level as reported at baseline or lower), the participant will complete the RiiQ™ Symptom Scale in the eDiary for a maximum of 29 days, per ARI episode.
Time frame: On Day 1 (pre-dose baseline); and then once daily from the time the participant triggers an ARI Alert in the eDiary until the ARI episode is resolved for a maximum of 29 days per ARI episode, up to 28 weeks after study drug dosing
Trough Plasma Concentration at 24 Weeks (C[trough24w]) Following Administration of CD388
Evaluation of the trough plasma concentration at 24 weeks (C\[trough24w\]) after study drug dosing. PK parameters will be assessed in approximately 120 participants at designated sites only.
Time frame: Based on sampling done at onsite visits on Day 85 (±3 days) and Day 197/EOS (±7 days)
Maximum Plasma Concentration (C[max]) Following Administration of CD388
Evaluation of the maximum plasma concentration (C\[max\]) after study drug dosing. PK parameters will be assessed in approximately 120 participants at designated sites only.
Time frame: At onsite visits done on Day 8, Day 29, and Day 85 (each ±3 days) and on Day 197/EOS (±7 days)
Area Under the Plasma Concentration-Time Curve (AUC) Following Administration of CD388
Evaluation of the area under the plasma concentration-time curve (AUC) after study drug dosing. PK parameters will be assessed in approximately 120 participants at designated sites only.
Time frame: At onsite visits done on Day 8, Day 29, and Day 85 (each ±3 days) and on Day 197/EOS (±7 days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Oct 2025, 12 months.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 12 months is above that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →